At its meeting on 18 July 2022 the Transparency Council adopted Opinion No. 110/2022 on the legitimacy of combining multiple sclerosis treatment drug programmes, i.e. B.29 and B.46.
Publication with the minutes of the Transparency Council meeting
At its meeting on 18 July 2022 the Transparency Council adopted Opinion No. 110/2022 on the legitimacy of combining multiple sclerosis treatment drug programmes, i.e. B.29 and B.46.
Publication with the minutes of the Transparency Council meeting